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Arterial function after successful renal transplantation.
Background. Renal transplantation is increasingly the pre-
ferred method of renal replacement therapy. Cardiovascular
disease is the major barrier to long-term survival for transplant
recipients. The aim of this study was to determine whether the
increased arterial stiffness of patients with chronic renal failure
is improved after successful renal transplantation.
Methods. The study involved a group of 36 patients, aged 27 to
68 years (mean ± SD, 46 ± 11 years) who had cardiovascular risk
assessment and measurements of carotid artery intima-media
thickness (IMT), arterial pulse wave velocity [aorto-femoral
(PWV a-f) and femoral-dorsalis pedis (PWV f-d)], systemic
arterial compliance (SAC), and arterial wave reflection (aug-
mentation index, AIx) performed before and 12 months after
successful renal transplantation. B-mode ultrasound measure-
ments were used to determine mean carotid IMT and applana-
tion tonometry techniques to determine SAC, AIx, PWV (a-f),
PWV (f-d), and central pressures. On each occasion the follow-
ing were also measured: fasting lipids, homocysteine (tHcy), red
cell folate, cobalamin, and fibrinogen levels.
Results. One year after transplantation, mean serum creati-
nine was 143 ± 47 lmol/L, and creatinine clearance 60 ± 16 mL/
min/1.74m2 (range 25 to 104 mL/min/1.74m2). Total and low-
density lipoprotein (LDL) cholesterol were significantly re-
duced. tHcy was decreased by 38% and normalized in 45%.
Systolic and diastolic blood pressure and mean arterial pres-
sure were all improved. From baseline to 12 months’ post-
transplantation, there was no significant change in carotid IMT
(mean IMT 0.76 ± 0.11 vs. 0.75 ± 0.14 mm, P = 0.28) or SAC
(0.45 ± 0.23 vs. 0.46 ± 0.22 units, P = 0.95), but PWV [PWV
(a-f) 9.6 ± 2.6 vs. 8.8 ± 2.2 m/sec, P = 0.007; PWV (f-d) 10.7 ±
1.8 vs. 8.4 ± 1.7 m/sec, P < 0.001] and AIx (24.3 ± 13.4 vs.
15.9 ± 11.4%, P = 0.003) improved. After adjusting for the dif-
ferences in blood pressure, the changes in PWV (a-f) were no
longer significant, but the differences in PWV (f-d) persisted.
The change in AIx remained significant after adjusting for dif-
ferences in heart rate, and the fall in AIx was greater in patients
on immunosuppression with tacrolimus compared with those
on cyclosporine.
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Conclusion. One year after successful renal transplantation,
improvement in cardiovascular risk factors was associated with
improvement in indices of arterial stiffness.
The most frequent cause of transplant failure in pa-
tients over 55 years is death with intact graft function
[1]. Cardiovascular disease is the most common cause of
post-transplantation death. In the Norwegian population,
Aakhus et al [2] reported a prevalence of cardiovascular
disease in renal transplant recipients of 14% compared
with 6% in the general population. The incidence of new
cardiovascular events in renal transplant recipients is 5-
fold greater than that predicted from Framingham data
for subjects of similar age and gender [3]. Pretransplant
cardiovascular disease is an important predictor of post-
transplant cardiovascular events [4, 5].
Patients with chronic renal failure on maintenance dial-
ysis treatment have a very high prevalence of cardiovas-
cular risk factors, and approximately one third have had
previous cardiovascular events (ischemic heart disease,
stroke) at the time of commencement of dialysis treat-
ment [6]. After successful renal transplantation, the risk
of subsequent cardiovascular disease falls substantially.
From the Australian and New Zealand dialysis and trans-
plant registry, the difference in mortality rates between
dialysis and transplantation populations is almost 5-fold:
15.7 and 3.2 per 100 patient-years, respectively [7]. The
populations cannot be strictly compared because lower
risk patients may be selected for transplantation; how-
ever, there are additional morbid risks as a consequence
of immunosuppression in the transplant population.
Renal transplantation is known to have beneficial ef-
fects on volume state, dyslipidemia, calcium/phosphate
metabolism, and hyperhomocysteinemia. Simultaneous
pancreatic transplantation, as is now often employed in
the diabetic patient with end-stage renal disease, has the
potential for additional benefits in that it can restore phys-
iologic insulin secretion and correct glucose metabolism.
Measurements of arterial pulse wave velocity [8] and
arterial wave reflection [9] are predictive of cardiovascu-
lar mortality in patients with chronic renal failure. Carotid
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artery intima-media thickness (IMT) is an established
surrogate marker of cardiovascular risk in elderly pop-
ulations [10], and at all ages is greater in chronic re-
nal failure patients than control patients [11]. This study
examined the hypothesis that these markers would im-
prove after successful renal transplantation, in parallel
with the improved prognosis from cardiovascular disease.
In this prospective study, carotid artery IMT and indices
of arterial stiffness and pressure wave reflection were
examined before and 12 months after successful renal
transplantation.
METHODS
The study involved a group of 36 patients who had
cardiovascular risk assessment, fasting blood sample col-
lection, and measurements of carotid artery IMT, arterial
pulse wave velocity (PWV), systemic arterial compliance
(SAC), and arterial wave reflection (augmentation index
AIx) performed before and 12 months after successful
renal transplantation.
Baseline studies were performed in all patients at
entry into the Atherosclerosis and Folic Acid Supple-
mentation Trial (ASFAST), an Australian/New Zealand
randomized, double-blind, placebo-controlled trial of
high dose folic acid therapy in patients with chronic re-
nal failure examining the hypothesis that progression of
atherosclerosis is related to hyperhomocysteinemia. Sub-
jects were included on the basis of age above 18 years,
chronic renal failure of any cause, serum creatinine of 0.40
mmol/L or greater, and awaiting commencement of dial-
ysis, or on continuous ambulatory peritoneal dialysis or
hemodialysis.
Those patients who had undergone renal transplanta-
tion during the first three years of follow-up were taken
off study protocol and asked to return one year post-
transplantation for reassessment. This involved 47 pa-
tients, 36 of whom were eligible on the basis of having
sustained allograft function, and who gave written in-
formed consent for the follow-up study, as approved by
the institutional research and ethics review board of each
participating center. Of those that did not complete one-
year visits, 2 were unable to return at year one, and 9 did
not wish to participate in the follow-up study.
Transplantation was performed from September of
1998 to June of 2001. Thirty-one patients underwent renal
transplantation (3 living-related and 28 cadaveric), and
5 had renal-pancreas transplantation. Mean time from
baseline assessment to transplantation was 15 ±9 months.
On the morning of study, subjects were advised to
take all usual therapy, including all antihypertensive
agents. Examinations were undertaken in a quiet, air-
conditioned room after 10 minutes of rest and the subject
lying supine. Subjects then underwent noninvasive mea-
surement of carotid artery IMT and arterial function:
SAC, pulse wave velocity (PWV), and central pressure
augmentation index (AIx). For those on hemodialysis,
measurements were performed on the day after dialysis.
A fasting blood sample was also collected for analysis
of plasma creatinine, calcium and phosphate, lipids, full
blood examination, folate, cobalamin, albumin, fibrino-
gen, and total plasma homocyst(e)ine (tHcy) at baseline
and 12 months after transplantation. Creatinine clear-
ance (CrCl, mL/min/1.74m2) was calculated using the
Cockcroft and Gault formula:
CrCl = (140 − age) × wt(kg)/Pcr
× 814(×0.85 for women)
where wt is lean body weight ([0.9 × (height −152)] + 50
for men; + 45.5 for women), and Pcr is plasma creatinine
(mmol/L).
Each subject completed a questionnaire assessing cardio-
vascular risk based on the National Heart Foundation of
Australia Risk Factor Prevalence study [12]. History of
previous cardiovascular disease, defined as previous ex-
perience of angina or myocardial infarction, and/or is-
chemic stroke, was corroborated with a review of all par-
ticipants’ hospital records.
Measurement of artery wall thickness (IMT)
Imaging studies of the common carotid artery were
performed using a high-resolution ultrasound machine
(Diasonics DRF-400, Milwaukee, WI, USA) and a hand-
held transducer with 7.5-MHz central frequency (7.5-SPC
mechanic sector transducer). A region 1.0 cm proximal to
the origin of the bulb of both the right and left common
carotid artery was identified by B-mode ultrasonography
[13]. The transducer was manipulated such that the near
wall of the carotid artery was parallel to the transducer
footprint, and the lumen maximized in the longitudinal
plane. Three images of each B-mode, taken at three dif-
ferent angles (anterior, lateral, medial) were recorded
and then digitized and saved on computer. Stored images
were then analyzed to determine artery wall IMT using a
customized software program [14]. The mean of 60 IMT
measurements from the far wall of both common carotid
arteries was used in the final data analysis to give mean
IMT values. Maximum values for IMT were also obtained
in each of the three planes of both common carotid ar-
teries, and averaged to give mean and maximum IMT for
each patient.
The same operator performed all image reading. The
repeatability of this measurement was assessed in a sub-
group (N = 20) of ASFAST study participants who re-
turned to the study center on 2 separate occasions 2
weeks apart without having changed any therapy. The
correlation coefficient for IMT between the 2 visits was
0.89, and the intraobserver coefficient of variation 10.4%.
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Measurement of arterial compliance and stiffness
Total SAC was estimated using the “area method,”
which requires measurement of volumetric blood flow
and associated driving pressure to derive an estimated
compliance over the total systemic arterial tree [15–
16]. A hand-held Doppler flow velocimeter (Multido-
plex MD1; Huntleigh Technology, Cardiff, UK) placed
on the suprasternal notch at the base of the neck was
used to estimate arterial blood flow. Aortic driving pres-
sure was estimated by applanation tonometry of the
right common carotid artery using a noninvasive pres-
sure transducer (Millar Mikro-tip; Millar Instruments,
Houston, TX, USA). Doppler flow and pressure traces
were recorded continually for 1 minute and analyzed over
10 cardiac cycles using purpose-written software. Blood
pressures, derived from carotid waveforms, were cali-
brated against diastolic and mean brachial artery blood
pressure measurements from the left arm. SAC was then
calculated according to the formula:
SAC = Ad/R(Pes − Pd)
R = MAP/Qmean = MAP/[r2 × Fmean]
r = 0.25 × BSA + 0.52
BSA = [0.425 × weight(kg) + 0.725
× height(cm) + 71.44]/10, 000
where Ad is area under the diastolic portion of the pulse
pressure contour; R is total peripheral resistance calcu-
lated as mean arterial blood pressure (MAP)/mean blood
flow (Qmean); Pes is end-systolic aortic blood pressure,
Pd is end-diastolic arterial blood pressure; r is aortic root
radius; Fmean is mean velocity; and BSA is body surface
area.
The same carotid blood pressure waveforms used for
determination of SAC were also analyzed to identify the
“shoulder” and “peak” of the waves [17]. AIx was then
calculated as the ratio of the pressure difference between
the shoulder of the wave and peak systolic pressure (P)
and the pulse pressure (PP) according to the formula:
AIx = (P/PP) × 100
The augmentation point (Pi) is reliably identified mathe-
matically as the first zero crossing from positive to nega-
tive after the beginning of systole of the third derivative
of the pressure waveform. A value for AIx is defined as
positive or negative, depending on whether Pi occurs be-
fore or after the peak pressure.
PWV measurements were obtained for both the aorto-
femoral [PWV (a-f)] and femoral-dorsalis pedis arte-
rial segments [PWV (f-d)] by the foot-to-foot method
[18–19]. Continuous pulse pressure wave signals were
recorded with two tonometers (Millar Mikro-tip, SPT-
301; Millar Instruments) positioned at both the base of
the right common carotid artery and over the femoral
artery, or over the femoral artery and the ipsilateral dor-
salis pedis artery. Distances from the carotid sampling
sites to the manubrium sternum, manubrium sternum
to femoral artery, and femoral artery to dorsalis pedis
were measured as straight lines between these points on
the body surface with a tape measure. The onset of the
pulse wave was defined as the point of intersection of
the end of diastole and beginning of systole, identified
from the waveform analysis as the maximum of the first
derivative of the pressure signal. The mean transit time
(t) between the feet of simultaneously recorded waves
was determined from 10 consecutive cardiac cycles. PWV
was calculated from the distance between measurement
points and the measured time delay (t) as follows:
PWV = D/t(m/second)
where D is distance in meters and t is the time interval
in seconds.
Determination of blood pressures
Brachial blood pressure recordings were taken at 5-
minute intervals throughout the imaging period using a
Dinamap device (Critikon Compact TS; Johnson & John-
son, North Ryde, New South Wales, Australia). The first
blood pressure recording was excluded, and all subse-
quent measurements averaged. Central blood pressure
was measured by applanation tonometry of the right
common carotid artery using a noninvasive pressure
transducer (Millar Instruments). Carotid artery pres-
sure waveforms were calibrated from mean and diastolic
blood pressures obtained from simultaneously assessed
brachial artery Dinamap pressure recordings.
Measurement of tHcy
Venous blood taken after an 8-hour fast was analyzed
for total plasma homocyst(e)ine (tHcy) using an Abbott
Fluorescence Polarization immunoassay (Abbott Labo-
ratories, Abbott Park, IL, USA) on an Abbott IMx An-
alyzer. The between run coefficient of variation for this
assay is 4.3% at a level of 12.5 lmol/L.
Data analysis
Statistical analysis was performed using Microsoft Ex-
cel 97 and SPSS version 10 for Windows program (SPSS,
Inc., Chicago, IL, USA). Data was checked for normality,
and results are reported as the mean ± standard deviation
for normally distributed variables. The Student paired
t test was used to determine the significance of differ-
ences between visits, with P < 0.05 considered statistically
significant. For variables where the data were not nor-
mally distributed, results are expressed as the geometric
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Table 1. Baseline patient characteristics
No. of patients 36
Sex
Male 27
Female 9
Age years 46 ± 11
Primary renal disease
Glomerulonephritis 31%
Diabetes 22%
Adult polycystic kidney disease 17%
Vascular 11%
Other 19%
Duration of dialysis months 26 ± 28
Hypertensiona 78%
Hypercholesterolemiaa 50%
Former smokers 42%
Current smokers 11%
Pack-years smokedb 21 ± 17
Ischemic heart diseasea 11%
Cerebrovascular diseasea 3%
aDocumented past history.
bPack years, number of cigarettes smoked divided by 20 and multiplied by
number of years smoked. Results are given as mean ± SD.
means with 95% CIs, and differences between visits were
assessed by nonparametric tests.
RESULTS
Clinical and biological parameters
The characteristics of the study population before
transplantation are shown in Table 1. Participants were
aged 27 to 68 years (mean age 46 ± 11 years). Thirty-
four patients (94%) were on maintenance dialysis (27
hemodialysis and 7 peritoneal dialysis) for periods rang-
ing from 1 to 95 months, and 2 (6%) had end-stage re-
nal disease but had not yet commenced dialysis. Primary
cause of end stage renal disease included glomeru-
lonephritis (31%), diabetes mellitus (22%), adult poly-
cystic kidney disease (17%), and vascular/hypertensive
disease (11%). Regarding reported cardiovascular risk
factors, 11% had previous ischemic heart disease, 22% di-
abetes, 53% smoking history, 50% hypercholesterolemia,
and 78% hypertension. Antihypertensive therapy was
taken by 58% of subjects and comprised calcium antag-
onists (31%), b-blockers (17%), angiotensin-converting
enzyme inhibitors or angiotensin II receptor antagonists
(33%), and a-blockers (11%). Folic acid supplementa-
tion (median dose 5 mg weekly) was taken by 42%.
One year after transplantation, mean serum creati-
nine was 143 ± 47 lmol/L and creatinine clearance 60 ±
16 mL/min/1.74m2 (range 25 to 104 mL/min/1.74m2).
The majority of subjects continued to have a function-
ing arteriovenous fistula (83% pretransplant vs. 81%
post-transplant). Immunosuppressive therapy included
cyclosporine A in 64%, and tacrolimus in 33%. Post-
transplantation, 92% of subjects were on antihyperten-
sive therapy, with a greater proportion also requiring
≥2 agents (33% pretransplant vs. 53% post-transplant).
The increase in antihypertensive drug use was accounted
for by the increased use of the calcium antagonist dil-
tiazem (31% pretransplant vs. 89% post-transplant), a
drug that is also employed to augment the plasma levels
of cyclosporine. Similar numbers of subjects were taking
agents from each of the other major classes of antihyper-
tensive drugs pre- and post-transplantation: b-blockers
(17% vs. 28%), angiotensin-converting enzyme inhibitors
or angiotensin II receptor antagonists (33% vs. 36%), and
a-blockers (11% vs. 6%). Folic acid supplementation was
now taken by only 5% of subjects.
Of the eight transplanted patients with diabetes, there
were only three who underwent kidney transplantation
alone, and thus, too few to examine for differences within
the diabetic group.
Plasma lipids before and after transplantation are given
in Table 2. Mean total and LDL cholesterol were sig-
nificantly reduced post-transplantation, as was the LDL
to high-density lipoprotein (HDL) ratio. Lipoprotein(a)
was also significantly lower, although still well above the
normal reference range.
Total homocysteine was decreased by 38% and normal-
ized in 45%, as shown in Table 3. There were significant
decreases in both red cell folate and plasma cobalamin
levels. Serum albumin and fibrinogen did not change sig-
nificantly with transplantation.
Blood pressures
Hemodynamic parameters are given in Table 4.
Brachial systolic blood pressure, diastolic blood pressure,
and mean arterial pressure were all improved one year af-
ter transplantation, independent of immunosuppressive
regimen. Pulse pressure did not change (61 ± 20 vs. 60 ±
16 mm Hg, P = 0.57), and neither did central systolic
blood pressure (127 ± 25 vs. 123 ± 18 mm Hg, P = 0.15)
nor central pulse pressure (46 ± 16 vs. 49 ± 16 mm Hg,
P = 0.25). Heart rate was significantly lower (71 ± 13 vs.
62 ± 11 beats/minute, P = 0.002) post transplantation.
Indices of artery structure and function
Indices of artery structure and function are divided by
immunosuppressive regimen and are shown in Tables 5
and 6. One year after successful renal transplantation
there was no significant change in carotid artery IMT
(mean IMT 0.76 ± 0.11 vs. 0.75 ± 0.14 mm, P = 0.28), total
peripheral resistance (17.0 ± 5.9 vs. 18.1 ± 5.6, P = 0.28),
or systemic arterial compliance (0.45 ± 0.23 vs. 0.46 ±
0.22 units, P = 0.95), but pulse wave velocities [PWV (a-
f) 9.6 ± 2.6 vs. 8.8 ± 2.2 m/sec, P = 0.007; PWV (f-d) 10.7 ±
1.8 vs. 8.4 ± 1.7 m/sec, P < 0.001] and AIx (24.3 ± 13.4 vs.
15.9 ± 11.4%, P = 0.003) improved.
The improvement in PWV was more marked distally
[ PWV (a-f) vs. PWV(f-d): −0.7 ± 1.4 vs. −2.4 ± 1.8
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Table 2. Comparison of lipid parameters pre- and post-transplantation
Pre-transplant Post-transplant  P value
Total cholesterol mmol/L 5.2 ± 1.1 4.8 ± 1.3 −0.4 ± 1.2 0.039
Triglycerides mmol/L 1.8 ± 1.0 1.6 ± 0.6 −0.2 ± 1.0 NS
LDL cholesterol mmol/L 3.2 ± 1.0 2.7 ± 1.1 −0.5 ± 0.9 0.007
HDL cholesterol mmol/L 1.3 ± 0.5 1.3 ± 0.5 0.1 ± 0.4 NS
LDL:HDL ratio 2.9 ± 1.7 2.2 ± 1.1 −0.7 ± 1.3 0.004
Lipoprotein a mg/La 520 (297, 743) 415 (240, 589) −125 (−235, −14) 0.04
NS, not significant at P < 0.05. Other results are given as mean ± SD.
aResult given as geometric mean (95% CI).
Table 3. Comparison of biochemical parameters pre- and post-transplantation
Pre-transplant Post-transplant  P value
Homocyst(e)ine lmol/La 24.8 (21.8, 27.7) 15.3 (13.5, 17.2) −9.4 (−11.9, −7.0) <0.001
Red cell folate nmol/La 1701 (1312, 2090) 1073 (885, 1260) −628 (−1036, −220) 0.002
Cobalamin pmol/La 501 (420, 582) 347 (298, 396) −164 (−246, −1) <0.001
Serum creatinine lmol/L 858 ± 291 143 ± 47 −717 ± 283 <0.001
Albumin g/L 39 ± 4 40 ± 4 1.8 ± 5 NS
Fibrinogen g/La 3.54 (3.01, 4.07) 3.42 (3.01, 3.84) 0.04 (−0.34, 0.43) NS
NS, not significant at P < 0.05. Other results are given as mean ± SD.
aResult given as geometric mean (95% CI).
Table 4. Comparison of hemodynamic parameters pre- and
post-transplantation
Pre- Post- P
transplant transplant  value
Brachial
Systolic BP mm Hg 144 ± 29 132 ± 20 −12 ± 25 0.014
Diastolic BP mm Hg 84 ± 14 74 ± 9 −11 ± 12 <0.001
Pulse Pressure mm Hg 61 ± 20 59 ± 16 −2 ± 15 NS
MAP mm Hg 105 ± 18 94 ± 13 −11 ± 16 0.001
Central
Systolic BP mm Hg 127 ± 25 123 ± 18 −7 ± 25 NS
Pulse ressure mm Hg 46 ± 16 49 ± 16 3 ± 16 NS
Heart rate bpm 71 ± 13 62 ± 11 −9 ± 17 0.002
Total peripheral 17.0 ± 5.9 18.1 ± 5.6 1.2 ± 5.9 NS
resistance mL/min
NS, not significant at P < 0.05. Results are given as mean ± SD.
m/sec], and similar in those recipients of renal and renal-
pancreas transplants [ PWV (a-f): −1.2 ± 1.0 vs. −0.6 ±
1.5 m/sec, P = 0.29; PWV (f-d): −1.6 ± 1.8 vs. −2.5 ±
1.8 m/sec, P = 0.34]. After adjustment for mean arterial
pressure, the change in PWV (a-f) was no longer appar-
ent [adjusted PWV (a-f) 9.1 ± 1.8 vs. 9.4 ± 1.6 m/sec, P =
0.11]; however, the improvement in PWV (f-d) remained
[adjusted PWV (f-d) 10.3 ± 2.4 vs. 9.1 ± 1.8 m/sec, P =
0.009]. The type of immunosuppression used did not ap-
pear to have any effect on the improvement in PWV
(Table 6).
There was a significant reduction in AIx that was in-
dependent of heart rate (heart rate adjusted AIx 22.8 ±
16.5 vs. 11.6 ± 18.8%, P = 0.012). The change in AIx in
renal and renal-pancreas recipients was similar ( AIx:
−11.0 ± 23.3 vs. −9.1 ± 15.2%, P = 0.82). Immunosup-
pression with cyclosporine appeared to abrogate the im-
provement in AIx. As depicted in Figure 2, one year after
transplantation the reduction in AIx in those on cy-
closporine was significantly less than those on tacrolimus.
DISCUSSION
Achieving a reduction in cardiovascular death is
a major goal in attempts to improve the prognosis
for patients post-transplantation. Improvement is seen
in several cardiovascular risk factors post-transplant.
There is frequently a reduction in blood pressure post-
transplantation mirroring the central blood pressure reg-
ulatory role of the kidney, but also contributing is the
increased use of vasoactive agents. Improvement in lipid
parameters also follows restoration of normal renal func-
tion post-transplantation; lipoprotein(a) is reduced [20],
and hypercholesterolemia is easier to control [21]. Such
changes were confirmed in our population: one year after
transplantation there was a general improvement in car-
diovascular risk factors including brachial blood pressure,
lipids, and homocyst(e)ine levels. After transplantation
the patients were on more vasoactive/antihypertensive
agents, largely attributed to the use of the calcium chan-
nel blocker diltiazem, employed as an immunosuppres-
sive sparing agent in patients receiving cyclosporine. The
increased use of diltiazem post-transplantation may also
have contributed to the fall in heart rate.
Improvement in the cardiovascular risk profile post-
transplantation has been associated with a reduction in
the clinical burden of cardiovascular disease among trans-
plant recipients compared with those who remain on dial-
ysis [7]. We sought to determine whether more subtle
subclinical markers of cardiovascular damage would be
similarly improved. Arterial stiffness as measured by
pulse wave velocity was significantly improved one year
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Table 5. Arterial indices pre- and post-transplantation
Pre-transplant Post-transplant  P value
Carotid IMT mm
Mean 0.76 ± 0.11 (36) 0.75 ± 0.14 (33) −0.02 ± 0.13 NS
Mean maximum 0.94 ± 0.14 (36) 0.92 ± 0.18 (33) −0.02 ± 0.10 NS
SAC mL/mm Hg 0.45 ± 0.23 (31) 0.46 ± 0.22 (31) 0.00 ± 0.23 NS
AIx % 24.3 ± 13.4 (31) 10.0 ± 16.6 (31) −14.3 ± 19.1 <0.001
Heart rate-adjusted 22.8 ± 16.5 11.6 ± 18.8 0.012
PWV m/sec
Aorto-femoral 9.5 ± 2.6 (31) 8.8 ± 2.2 (31) −0.7 ± 1.4 0.007
MAP-adjusted 9.1 ± 1.8 9.4 ± 1.6 0.11
Femoro-distal 10.7 ± 1.8 (28) 8.4 ± 1.7 (28) −2.4 ± 1.8 <0.001
MAP-adjusted 10.3 ± 2.4 9.1 ± 1.8 0.009
NS, not significant at P < 0.05 Results are given as mean ± SD (number of patients).
Table 6. Comparison of arterial indices according to immunosuppression
Pre-transplant Post-transplant  (%)
Cyclosporine Tacrolimus Cyclosporine Tacrolimus Cyclosporine Tacrolimus P value
Brachial mm Hg
Systolic BP 142 ± 25 148 ± 36 133 ± 16 132 ± 25 −10 ± 25 −16 ± 25 0.50
Diastolic BP 84 ± 13 83 ± 15 73 ± 8 72 ± 12 −11 ± 14 −11 ± 10 0.93
Pulse pressure 58 ± 18 65 ± 25 60 ± 15 60 ± 19 0.4 ± 14 −5 ± 17 0.35
Central
Systolic BP mm Hg 129 ± 24 123 ± 28 124 ± 15 121 ± 23 −7 ± 27 −5 ± 21 0.81
Pulse pressure mm Hg 48 ± 16 43 ± 19 51 ± 14 47 ± 21 3 ± 16 3 ± 18 0.99
Heart rate bpm 71 ± 15 70 ± 11 59 ± 9 68 ± 11 −12 ± 17 −2 ± 15 0.09
Carotid IMT mm
Mean max 0.96 ± 0.15 0.91 ± 0.10 0.96 ± 0.20 0.84 ± 0.12 −0.00 ± 0.12 −0.07 ± 0.12 0.14
Mean 0.78 ± 0.12 0.73 ± 0.07 0.78 ± 0.15 0.68 ± 0.12 −0.01 ± 0.09 −0.04 ± 0.11 0.35
SAC mL/mm Hg 0.46 ± 0.26 0.43 ± 0.18 0.43 ± 0.18 0.51 ± 0.27 −0.03 ± 0.21 0.08 ± 0.26 0.27
TPR mL/min 16.8 ± 5.9 17.3 ± 6.1 18.8 ± 6.2 16.9 ± 4.2 2.03 ± 5.62 −0.44 ± 6.12 0.29
AIx % 22.9 ± 15.2 27.2 ± 8.6 14.9 ± 13.1 −0.2 ± 19.1 −8.0 ± 16.5 −27.4 ± 18.2 0.01
Heart rate-adjusted 21.2 ± 18.6 26.2 ± 11.1 17.8 ± 14.5 −1.4 ± 20.8 −3.4 ± 20.6 −27.6 ± 21.0 <0.01
PWV m/sec
Aorto-femoral 9.4 ± 2.0 9.9 ± 3.6 8.7 ± 1.8 9.1 ± 3.0 −0.7 ± 1.4 (7%) −0.8 ± 1.5 (8%) 0.81
Femoro-distal 11.2 ± 1.4 9.9 ± 2.1 9.0 ± 1.4 7.3 ± 1.7 −2.2 ± 1.9 (20%) −2.7 ± 1.7 (27%) 0.51
Results are given as mean ± SD (% change from baseline). P value for difference between groups.
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Fig. 1. Change in augmentation index (AIx) with transplantation.
after renal transplantation. There was a 7% reduction
in PWV (a-f) and a 22% reduction in PWV (f-d). This
improvement was seen in both kidney and combined
kidney-pancreas transplant recipients. After adjusting for
differences in blood pressure, the change in PWV (a-f)
was no longer significant, but the improvement in PWV
(f-d) was still observed, implying reduced peripheral
artery stiffness independent of blood pressure lowering.
The greater improvement seen in peripheral compared
with central PWV may reflect the propensity of distal
muscular arteries to be more responsive to changes in vol-
ume state, sympathetic innervation, and neurohumoral-
mediated vasomotor tone. Another possible explanation
is an effect of the calcium channel blockade on pulse wave
velocity [22].
It has previously been shown that central PWV is an in-
dependent predictor of cardiovascular and all-cause mor-
tality in patients with CRF and hypertension [8, 23]. It
has also been shown that the loss of reversibility of aor-
tic stiffness to blood pressure lowering is a major factor
contributing to the mortality of CRF patients [24]. In
the study by Guerin et al, the CRF patients whose cen-
tral PWV did not improve with blood pressure lowering
exhibited substantially worse survival than those whose
PWV did. This transplanted population has exhibited an
improvement in central PWV and arterial stiffness that is
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Fig. 2. Comparison of augmentation index
(AIx) pre- and post-transplantation in pa-
tients on cyclosporine- and tacrolimus-based
immunosuppression. Data are mean ± stan-
dard deviation for each treatment group.
accounted for by the change in blood pressure. It remains
that change in PWV should always be interpreted with
caution, and only after adjustment for change in blood
pressure.
Central pressure augmentation was also significantly
improved one year after renal transplantation. There was
a 49% reduction in mean AIx adjusted for heart rate. Be-
cause there was no change in peripheral vascular resis-
tance, this is also in keeping with a significant reduction
in arterial stiffness.
The decrease in heart rate adjusted AIx was not associ-
ated with a decrease in central systolic pressure, despite
a significant reduction in brachial blood pressures. This
appears paradoxical, because central to peripheral blood
pressure amplification is expected to increase with a de-
crease in AIx; the most likely explanation is that post-
transplantation there is a reduced degree of distal wave
reflection. This may be explained, at least in part, by the
allograft providing a new vascular bed, and thus, altering
the arterial wave reflection point. A second possibility is
that improved cardiac function post-transplantation re-
sulted in a higher amplitude incident pressure wave. This
latter possibility seems less likely as stroke volume actu-
ally decreased after transplantation.
Irrespective of the cause of the improvement in AIx,
the change appeared to be abrogated by the calcineurin
inhibitor, cyclosporine. In a recent study, cyclosporine
therapy was associated with an increase in AIx in re-
nal transplant recipients [25]. The detrimental effect of
cyclosporine on blood pressure and glomerular filtra-
tion rate in healthy subjects is well established [26].
Tacrolimus, at least in healthy subjects, does not appear
to have this effect. Greater activation of the sympathetic
nervous system by cyclosporine is one possible explana-
tion for the differences in AIx observed between the two
different immunosuppressive regimens. The two drugs
may also have different effects on other systemic vaso-
constrictors [27]. There was, however, no difference in
blood pressure at 12 months between these two treat-
ment groups. The other possibility is that tacrolimus is
anti-proliferative and able to have a better effect on re-
modeling of peripheral conduit arteries, which are the
major site for arterial wave reflection.
Proximal aortic compliance did not change after trans-
plantation. This is consistent with the nonsignificant
change in central PWV after adjustment for blood pres-
sure. Loss of elastic tissue and central calcification in cen-
tral arteries may lead to irreversible structural change.
Furthermore, in the presence of unchanged proximal aor-
tic compliance, the decrease in heart rate should allow for
a longer systolic and diastolic run-off time and lead to a
decrease in diastolic blood pressure, as was observed.
We have previously reported a 10 to 15 year shift to the
right in the age-related increase in carotid IMT in the dial-
ysis population [28]. There was no significant change in
carotid IMT at one year after transplantation, but larger
numbers and a longer period of observation would be
needed to detect a change in this variable.
CONCLUSION
After successful renal transplantation there is overall
improvement in cardiovascular risk factors. PWV and
AIx return to more normal levels, reflecting improvement
in blood pressure control, but also reduced artery stiff-
ness and reduced peripheral pressure wave reflectance.
These are reproducible and simple noninvasive measure-
ments that could be more widely applied in the long-term
monitoring of patients with chronic renal failure and re-
nal transplantation. Our data showing a marked improve-
ment in AIx in the tacrolimus-treated group when com-
pared with the cyclosporine treated group supports the
theory that tacrolimus immunosuppression may in the
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long term be better for cardiovascular outcome in renal
transplant recipients.
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